Drugs / Tocofersolan
last change Jan 2023 re-read 3 minutes ago

Tocofersolan

Small molecule

Developed for
hypobetalipoproteinemia · vitamin deficiency disorder
Investigated by
Boston Children's Hospital · Hospices Civils de Lyon

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved EU (EMA) Vedrop — 2009-07-23 europa.eu ↗

Trials 2

201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT03582384 Dec 2020 → Jan 2022 short bowel syndrome, vitamin deficiency disorder Boston Children's Hospital Withdrawn No outcome recorded
Phase 31 trial
Phase 3 NCT01457690 Oct 2011 → Aug 2015 hypobetalipoproteinemia Hospices Civils de Lyon Completed No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as Tocofersolan ClinicalTrials.gov intervention name — accepted as the source's own label NCT01457690 ↗
1

NCT03582384 ↗

Known as Liqui-e ChEMBL registry synonym — accepted as the source's own label CHEMBL2108106 ↗
Known as Tocophersolan ChEMBL registry synonym — accepted as the source's own label CHEMBL2108106 ↗
Known as TPG-S ChEMBL registry synonym — accepted as the source's own label CHEMBL2108106 ↗
Known as Vedrop “Use of Tocofersolan (Vedrop®) to Prevent or Treat Refractive Vitamin E Deficiency in Infants and Children” NCT03582384 ↗
Known as Vitamin e polyethylene glycol succinate ChEMBL registry synonym — accepted as the source's own label CHEMBL2108106 ↗
Modality Small molecule — CHEMBL2108106 ↗
Route Oral “The aims of this study were to evaluate the intestinal absorption characteristics of tocofersolan versus α-tocopherol acetate by measuring the plasma concentrations of...” PMID 30021760 ↗ Jul 2018